Advanced Recurrent Ovarian Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "Advanced Recurrent Ovarian Cancer Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Advanced Recurrent Ovarian Cancer pipeline landscape. It covers the Advanced Recurrent Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Recurrent Ovarian Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Advanced Recurrent Ovarian Cancer Pipeline Report
• DelveInsight's Advanced Recurrent Ovarian Cancer Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Advanced Recurrent Ovarian Cancer.
• The leading Advanced Recurrent Ovarian Cancer Companies include IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH, and others.
• Promising Advanced Recurrent Ovarian Cancer Pipeline Therapies includes Pembrolizumab, MEDI3617, Bevacizumab, Paclitaxel, Carboplatin, MM-121, DOXIL, Dexamethasone, BAY2287411, and others.
• May 2024:- Verismo Therapeutics- A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma. This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
• May 2024:-- Dragonfly Therapeutics- A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors.
• May 2024:- Eli Lilly and Company- The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

To explore more information on the latest breakthroughs in the Advanced Recurrent Ovarian Cancer treatment landscape of the report, click here @ Advanced Recurrent Ovarian Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Advanced Recurrent Ovarian Cancer Overview
Ovarian cancer refers to cancer that arises in the almond-shaped reproductive organs in women in which eggs, or ova, are produced (ovaries), in either of the two tubes through which eggs travel from the ovaries to the uterus (fallopian tubes), or in the membrane that lines the pelvis and the abdominal cavity and covers all of the abdominal organs (peritoneum). There are usually no symptoms (asymptomatic) during the early stages. As a result, ovarian cancer is usually not diagnosed until an advanced stage. Common symptoms that can develop include abdominal swelling or bloating, unintended weight loss, or changes in the bowel habits including constipation.

Some women have advanced ovarian cancer when they are first diagnosed, and treatment can cure their cancer. This depends on several factors, including the exact stage of the cancer. But for more advanced cancers, or those that come back after treatment, the aim of treatment is usually to: shrink the cancer, control it for as long as possible - this might be for many months and sometimes years, or control the symptoms.

Advanced Recurrent Ovarian Cancer Emerging Drugs Profile

• Maveropepimut S: IMV
Maveropepimut-S (DPX-Survivac) combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV's new class of immunotherapies that generates cancer-targeted T cells in vivo. The protein survivin is found in more than 15 types of solid tumor and hematologic cancers. It has been recognized as a promising tumor-associated target because it is overexpressed in a high percentage of tumor types. It is believed Maveropepimut-S' ability to deliver a sustained flow of T cells that target survivin expressed on cancer cells can lead to more clinically effective anti-tumor therapies. Maveropepimut-S has demonstrated a robust and sustained, antigen-specific immune response with infiltration of targeted T cells into tumors post-treatment which is correlated with prolonged duration of clinical benefits up to more than two years. Maveropepimut-S showed a well-tolerated safety profile with no immune-related, serious systemic adverse events reported. Majority of adverse events being grade 1 and 2 injection site reactions. Compared to traditional immuno-oncology therapies, which require intravenous infusions and safety monitoring, Maveropepimut-S provides lesser burden on patients' quality of life.

• ELU 001: Elucida Oncology
ELU001 is a novel, first-in-class, new molecular entity described as a C'Dot Drug Conjugate (CDC). ELU001 consists of ~12 folic acid targeting moieties and ~22 exatecan topoisomerase-1 inhibitor payloads on Cathepsin-B cleavable linkers covalently bound to the surface of each silicon core/polyethylene glycol C'Dot nanoparticle. CDCs are small in size, have a greater ability to penetrate into and through tumors as compared to ADCs, and are rapidly eliminated by the kidneys. The rapid systemic elimination is expected to lead to less toxicity than is observed with targeting platforms like ADCs that have a longer half-life in circulation. ELU001's high avidity is believed to promote internalization into FRα overexpressing cancer cells, selectively delivering its payload. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

• A166: Klus Pharma
A166 is a third-generation antibody-drug conjugate (ADC) that incorporates an anti-HER2 antibody conjugated to highly potent auristatin-based payload, via site-specific conjugation and cleavable Val-Cit linker. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

For further information, refer to the detailed Advanced Recurrent Ovarian Cancer Unmet Needs, Advanced Recurrent Ovarian Cancer Market Drivers, and Advanced Recurrent Ovarian Cancer Market Barriers, click here for Advanced Recurrent Ovarian Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Advanced Recurrent Ovarian Cancer Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Advanced Recurrent Ovarian Cancer. The companies which have their Advanced Recurrent Ovarian Cancer drug candidates in the most advanced stage, i.e. phase II include, IMV.

DelveInsight's Advanced Recurrent Ovarian Cancer Pipeline Report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request a sample and discover the recent advances in Advanced Recurrent Ovarian Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Advanced Recurrent Ovarian Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Advanced Recurrent Ovarian Cancer Companies
IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH, and others.

Advanced Recurrent Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Advanced Recurrent Ovarian Cancer Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Dive deep into rich insights for drugs for Advanced Recurrent Ovarian Cancer Pipeline, click here @ Advanced Recurrent Ovarian Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Advanced Recurrent Ovarian Cancer Pipeline Report
• Coverage- Global
• Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Advanced Recurrent Ovarian Cancer Companies- IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH, and others.
• Advanced Recurrent Ovarian Cancer Pipeline Therapies- Pembrolizumab, MEDI3617, Bevacizumab, Paclitaxel, Carboplatin, MM-121, DOXIL, Dexamethasone, BAY2287411, and others.
• Advanced Recurrent Ovarian Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Advanced Recurrent Ovarian Cancer Mergers and acquisitions, Advanced Recurrent Ovarian Cancer Licensing Activities @ Advanced Recurrent Ovarian Cancer Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Advanced Recurrent Ovarian Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Recurrent Ovarian Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Maveropepimut S: IMV
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Advanced Recurrent Ovarian Cancer Key Companies
21. Advanced Recurrent Ovarian Cancer Key Products
22. Advanced Recurrent Ovarian Cancer- Unmet Needs
23. Advanced Recurrent Ovarian Cancer- Market Drivers and Barriers
24. Advanced Recurrent Ovarian Cancer- Future Perspectives and Conclusion
25. Advanced Recurrent Ovarian Cancer Analyst Views
26. Advanced Recurrent Ovarian Cancer Key Companies
27. Appendix

List of Important Links-
https://www.wowonder.xyz/read-blog/65223
https://diccut.com/germandennydones
https://us.newyorktimesnow.com/dennydones9193
https://www.mymeetbook.com/germanydennydones
https://wiwonder.com/1716272393254738_2674
https://www.japanesewomenorg.com/read-blog/15585
https://tannda.net/read-blog/62770
https://evahno.com/read-blog/22402
https://www.pickmemo.com/read-blog/307268
https://ai.ceo/read-blog/132421
https://www.truthsocialviet.com/read-blog/58205
https://hanzuzhisheng.com/read-blog/489
https://www.testimonyforgod.com/read-blog/3019
https://www.skillsire.com/germandennydones
https://meetplayer.com/8a48fed02
https://zekond.com/read-blog/37531
https://shareyoursocial.com/germanydennydones
https://www.snipesocial.co.uk/dennydones9911
https://social.studentb.eu/read-blog/182065

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.